{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:07:18Z","timestamp":1789056438996,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201809","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:44:01Z","timestamp":1783640641000},"page":"201809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Co-delivery of lentiviral vectors and Cas9-containing virus-like particles enables rapid, scalable manufacture of gene-edited CAR T cells"],"prefix":"10.1016","volume":"34","author":[{"given":"Francesca","family":"Ferrara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M.","family":"Wielgosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeoungeun J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bauler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Wincek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataly","family":"Mier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon R.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan A.","family":"Beard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna M.","family":"Langfitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9191-4742","authenticated-orcid":false,"given":"Robert E.","family":"Throm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201809_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201809_bib2","article-title":"Mapping the clinical landscape of multifunctional CAR T cells: targets, trends, and synergies","author":"Ogusuku","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201809_bib3","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201809_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omta.2026.201809_bib5","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ceja","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omta.2026.201809_bib6","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201809_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201809_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201809_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201809_bib10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/cancers12020375","article-title":"Design and Characterization of an \u201cAll-in-One\u201d Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines","volume":"12","author":"Zimmermann","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.omta.2026.201809_bib11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201809_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.semcancer.2017.02.010","article-title":"The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells","volume":"45","author":"Ramachandran","year":"2017","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.omta.2026.201809_bib13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1089\/hum.2023.128","article-title":"Genome Editing in Engineered T Cells for Cancer Immunotherapy","volume":"34","author":"Bonini","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201809_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh0272","article-title":"Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity","volume":"13","author":"Prinzing","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201809_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201809_bib16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201809_bib17","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.omta.2026.201809_bib18","article-title":"Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201809_bib19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40164-023-00435-w","article-title":"Current approaches to develop \u201coff-the-shelf\u201d chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review","volume":"12","author":"Aparicio","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.omta.2026.201809_bib20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine Base Editing Enables Quadruple-Edited Allogeneic CAR-T Cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201809_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41467-018-07845-z","article-title":"Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins","volume":"10","author":"Mangeot","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201809_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109207","article-title":"Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering","volume":"35","author":"Hamilton","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.omta.2026.201809_bib23","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1016\/j.cell.2023.08.041","article-title":"Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells","volume":"186","author":"Tsuchida","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201809_bib24","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/s41587-022-01377-0","article-title":"Frequent aneuploidy in primary human T cells after CRISPR\u2013Cas9 cleavage","volume":"40","author":"Nahmad","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omta.2026.201809_bib25","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3390\/ijms23031689","article-title":"Challenges of CRISPR-Based Gene Editing in Primary T Cells","volume":"23","author":"Rezalotfi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2026.201809_bib26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.omtn.2018.05.010","article-title":"VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9","volume":"12","author":"Montagna","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omta.2026.201809_bib27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201809_bib28","article-title":"Cell type-programmable genome editing with enveloped delivery vehicles","volume":"2022","author":"Hamilton","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.omta.2026.201809_bib29","article-title":"Baboon Envelope Pseudotyped \u201cNanoblades\u201d Carrying Cas9\/gRNA Complexes Allow Efficient Genome Editing in Human T, B, and CD34+ Cells and Knock-in of AAV6-Encoded Donor DNA in CD34+ Cells","volume":"3","author":"Gutierrez-Guerrero","year":"2021","journal-title":"Frontiers Genome"},{"key":"10.1016\/j.omta.2026.201809_bib30","doi-asserted-by":"crossref","first-page":"10059","DOI":"10.1093\/nar\/gkad676","article-title":"Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR\/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification","volume":"51","author":"Haldrup","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omta.2026.201809_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.omtm.2023.03.006","article-title":"Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles","volume":"29","author":"Jo","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201809_bib32","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omta.2026.201809_bib33","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41587-023-02078-y","article-title":"Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo","volume":"42","author":"An","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omta.2026.201809_bib34","first-page":"1","article-title":"In vivo gene editing of human hematopoietic stem and progenitor cells using envelope-engineered virus-like particles","author":"Botchkarev","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omta.2026.201809_bib35","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1093\/nar\/gkz605","article-title":"Delivering Cas9\/sgRNA ribonucleoprotein (RNP) by lentiviral capsid-based bionanoparticles for efficient \u2018hit-and-run\u2019 genome editing","volume":"47","author":"Lyu","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omta.2026.201809_bib36","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41467-020-14957-y","article-title":"Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping","volume":"11","author":"Gee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201809_bib37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-026-00767-z","article-title":"Advances in Engineered Virus-Like Particles for Genome Editing and Therapy","volume":"40","author":"Son","year":"2026","journal-title":"BioDrugs"},{"key":"10.1016\/j.omta.2026.201809_bib38","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.cell.2013.12.001","article-title":"Dynamic Imaging of Genomic Loci in Living Human Cells by an Optimized CRISPR\/Cas System","volume":"155","author":"Chen","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201809_bib39","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41587-020-0555-7","article-title":"CHANGE-seq reveals genetic and epigenetic effects on CRISPR\u2013Cas9 genome-wide activity","volume":"38","author":"Lazzarotto","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omta.2026.201809_bib40","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1039\/b819201d","article-title":"Microscale electroporation: challenges and perspectives for clinical applications","volume":"1","author":"Lee","year":"2009","journal-title":"Integr. Biol."},{"key":"10.1016\/j.omta.2026.201809_bib41","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/14760584.2025.2508517","article-title":"Virus-like particles: a versatile and effective vaccine platform","volume":"24","author":"Bachmann","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.omta.2026.201809_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1123805","article-title":"Platforms, advances, and technical challenges in virus-like particles-based vaccines","volume":"14","author":"Gupta","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201809_bib43","doi-asserted-by":"crossref","first-page":"16998","DOI":"10.1073\/pnas.1101874108","article-title":"Protein delivery using engineered virus-like particles","volume":"108","author":"Kaczmarczyk","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201809_bib44","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tim.2012.11.006","article-title":"HIV Gag polyprotein: processing and early viral particle assembly","volume":"21","author":"Bell","year":"2013","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.omta.2026.201809_bib45","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3390\/v13020268","article-title":"Lentiviral Vector Bioprocessing","volume":"13","author":"Perry","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.omta.2026.201809_bib46","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.omtm.2019.11.011","article-title":"Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free Media","volume":"17","author":"Bauler","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201809_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101270","article-title":"Genetic alteration of SJ293TS cells and modification of serum-free media enhances lentiviral vector production","volume":"32","author":"Bauler","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201809_bib48","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/bloodadvances.2018027508","article-title":"Baboon envelope LVs efficiently transduced human adult, fetal, and progenitor T cells and corrected SCID-X1 T-cell deficiency","volume":"3","author":"Bernadin","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201809_bib49","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/leu.2016.372","article-title":"Baboon envelope pseudotyped lentiviral vectors: a highly efficient new tool to genetically manipulate T-cell acute lymphoblastic leukaemia-initiating cells","volume":"31","author":"Costa","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.omta.2026.201809_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2005840","article-title":"In vitro\u2013transcribed guide RNAs trigger an innate immune response via the RIG-I pathway","volume":"16","author":"Wienert","year":"2018","journal-title":"PLoS Biol."},{"key":"10.1016\/j.omta.2026.201809_bib51","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jim.2012.11.006","article-title":"Analysis of TCR activation kinetics in primary human T cells upon focal or soluble stimulation","volume":"387","author":"Arndt","year":"2013","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.omta.2026.201809_bib52","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/14653240801982961","article-title":"Retronectin\u00ae-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield","volume":"10","author":"Lamers","year":"2008","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omta.2026.201809_bib53","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1089\/hum.2019.157","article-title":"Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System Manufacturing","volume":"30","author":"Radek","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201809_bib54","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2427216122","article-title":"Quadruple adenine base\u2013edited allogeneic CAR T cells outperform CRISPR\/Cas9 nuclease\u2013engineered T cells","volume":"122","author":"Engel","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201809_bib55","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells","volume":"25","author":"Wu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201809_bib56","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.15252\/emmm.201708148","article-title":"Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy","volume":"9","author":"Milani","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omta.2026.201809_bib57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201809_bib58","doi-asserted-by":"crossref","first-page":"W171","DOI":"10.1093\/nar\/gkz365","article-title":"CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing","volume":"47","author":"Labun","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omta.2026.201809_bib59","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.omtm.2020.06.024","article-title":"The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing","volume":"18","author":"Riberdy","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201809_bib60","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.omto.2020.06.018","article-title":"Route of 41BB\/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28\u03b6 T Cells","volume":"18","author":"Nguyen","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omta.2026.201809_bib61","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.omta.2026.201809_bib62","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ymthe.2017.04.028","article-title":"Eliminating HIV-1 Packaging Sequences from Lentiviral Vector Proviruses Enhances Safety and Expedites Gene Transfer for Gene Therapy","volume":"25","author":"Vink","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201809_bib63","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1038\/s41598-019-40896-w","article-title":"CRIS.py: A Versatile and High-throughput Analysis Program for CRISPR-based Genome Editing","volume":"9","author":"Connelly","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:16:30Z","timestamp":1789053390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X26001448"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201809","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-delivery of lentiviral vectors and Cas9-containing virus-like particles enables rapid, scalable manufacture of gene-edited CAR T cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201809"}}